Aprea Therapeutics, Inc. Logo

Aprea Therapeutics, Inc.

Developing precision cancer therapies targeting DNA Damage Response for solid tumors.

APRE | US

Overview

Corporate Details

ISIN(s):
US03836J1025
LEI:
Country:
United States of America
Address:
3805 OLD EASTON ROAD, 18902 DOYLESTOWN
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel cancer therapeutics through precision oncology. The company specializes in synthetic lethality-based therapies that target DNA Damage Response (DDR) pathways. Aprea's pipeline features small molecule drug candidates designed to maximize clinical efficacy while minimizing toxicity. The company is actively conducting clinical trials to evaluate its programs in patients with advanced solid tumors, aiming to provide new treatment options and improve outcomes for cancer patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Aprea Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Aprea Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Aprea Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Opthea Ltd Logo
Biopharma that discontinued its wet AMD therapy after its lead drug failed Phase 3 trials.
United States of America OPT
OPTUS Pharmaceutical Co., Ltd. Logo
Develops and manufactures ophthalmic solutions for dry eye, infections, and inflammation.
South Korea 131030
Opus Genetics, Inc. Logo
Developing gene therapies for inherited retinal diseases and other blinding conditions.
United States of America IRD
ORAGENICS INC Logo
Biotech developing intranasal drugs for concussion and other brain disorders.
United States of America OGEN
Oramed Pharmaceuticals Inc. Logo
Develops oral drug delivery systems to turn injectable drugs, like insulin, into oral therapies.
Israel ORMP
ORASURE TECHNOLOGIES INC Logo
Develops and distributes point-of-care diagnostic tests and sample collection devices.
United States of America OSUR
Orexo Logo
Develops pharmaceuticals & digital health for opioid use disorder in the US market.
Sweden ORX
ORGANIGRAM GLOBAL INC. Logo
Licensed producer of indoor-grown cannabis and derived products for medical & recreational consumers.
United States of America OGI
Organon & Co. Logo
A global healthcare company focused on women's health, biosimilars, and established brands worldwide.
United States of America OGN
Oric Pharmaceuticals, Inc. Logo
Developing therapies to overcome resistance in lung and prostate cancer.
United States of America ORIC

Talk to a Data Expert

Have a question? We'll get back to you promptly.